scispace - formally typeset
Search or ask a question
Author

Shalini Sharma

Bio: Shalini Sharma is an academic researcher. The author has contributed to research in topics: Insulin resistance & Arteriosclerosis. The author has an hindex of 5, co-authored 23 publications receiving 152 citations.

Papers
More filters
Patent
22 Jan 2007
TL;DR: In this article, compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

105 citations

Patent
13 Mar 2009
TL;DR: In this paper, the use of a compound represented by Formula IA or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a condition in a mammalian subject is described.
Abstract: Described herein is the use of a compound represented by Formula IA or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a condition in a mammalian subject, the condition being gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, or tumor-lysis syndrome: (see formula IA)

11 citations

Patent
09 Feb 2004
TL;DR: In this paper, compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

8 citations

Patent
30 Apr 2009
TL;DR: In Formula 1, x is 1 or 2: y is 0, 1, 2 or 3; and R1 is selected from the group consisting of hydrogen, alkyl having 1 or two carbon atoms, hy-droxy, alkoxy, chloro, bromo, and amino as discussed by the authors.
Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions in-cluding gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyper-uricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syn-drome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation. In Formula 1, x is 1 or 2: y is 0, 1, 2 or 3; and R1 is selected from the group consisting of hydrogen, alkyl having 1 or 2 carbon atoms, hy-droxy, alkoxy having 1 or 2 carbon atoms, fluoro. chloro, bromo, and amino. A is phenyl unsubstituted or substituted by one, two or three groups selected from the group consisting of halo, alkyl having 1 or 2 carbon atoms. perfluoromethyL alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring atoms wherein the cycloalky! is unsubstituted or one one two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heleraromatic ring having 1 or 2 ring heteroatoms selected from N. S and 0 and the heteroaromatic ring is covalently bound to the remainder of the compound by a ring carbon.

7 citations

Patent
02 Jul 2007
TL;DR: In this article, compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

5 citations


Cited by
More filters
Patent
04 Feb 2008
TL;DR: In this article, the authors provide compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue.
Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

125 citations

Patent
16 Jul 2004
TL;DR: In this paper, the authors describe pan-active compounds that are active on PPARs and methods for developing or identifying compounds having a desired selectivity profile, including panactive compounds.
Abstract: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

113 citations

Patent
20 Dec 2002
TL;DR: Coumpounds, compositions and methods for modulating the activity of nuclear receptors are provided in this paper, in particular, heterocyclic compounds are provided to modulate the activation of liver X receptor (LXR) and orphan nuclear receptors.
Abstract: Coumpounds, compositions and methods for modulating the activity of nuclear receptors are provided In particular, heterocyclic compounds are provided for modulating the activity of nuclear receptors, including liver X receptor (LXR) and orphan nuclear receptors In certain embodiments, the compounds are N-substituted pyridones

109 citations

Patent
22 Jan 2007
TL;DR: In this article, compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

105 citations

Patent
07 Dec 2007
TL;DR: In this article, the authors proposed a modulator of the activity of liver X receptors (LXR) and Farnesoid X receptor (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined.
Abstract: Compounds of the invention are disclosed, such as compounds of formulae LX - LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

70 citations